View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 21, 2021updated 22 Nov 2021 7:19am

GSK to sell stake in Innoviva for $392m

GlaxoSmithKline to sell its entire stake in royalty management company Innoviva for total proceeds of nearly $392m.

GlaxoSmithKline (GSK) has entered a definitive agreement to sell its entire equity stake in royalty management company Innoviva at $12.25 for each share, taking the deal proceeds to a total of nearly $392m.

According to the agreement, GSK will sell its roughly 32 million shares or 32% of the outstanding common stock back to Innoviva at a 3% discount.

Innoviva CEO Pavel Raifeld said: “We view the buyback as a compelling and highly accretive transaction demonstrating our ability to act strategically and opportunistically at the same time.

“We believe that it materially accelerates the delivery of our strategy while also meaningfully improving our shares’ long-term trading dynamics with an aligned shareholder base.”

This deal settlement will provide GSK with funds to further invest in its planned priorities. The company added that on concluding the equity disposal, it will not own any Innoviva stock.

For this transaction, Moelis was the financial advisor while Willkie Farr Gallagher was the legal advisor to Innoviva.

GSK noted that the terms of the company’s respiratory partnership with Innoviva will not be affected by this sale. Under the collaboration, Innoviva receives royalty payments for Trelegy Ellipta, Relvar/Breo Ellipta and Anoro Ellipta from GSK.

In September last year, the US Food and Drug Administration (FDA) granted approval for a new indication for Trelegy Ellipta to treat asthma in adults. It is also indicated for use in chronic obstructive pulmonary disease patients.

Trelegy Ellipta sales generated $1.16bn (£819m) last year while Relvar/Breo Ellipta and Anoro Ellipta sales generated revenue of $1.4bn (£1.1bn) and $776m (£547m), respectively.

Last month, GSK reported an 18% year-on-year (YOY) decline in revenue in the first quarter of this year to £7.41bn and down 15% at constant currency due to disruption caused by the global Covid-19 pandemic.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU